News | March 18, 2021
Merck accelerates expansion plans for single-use products critical to manufacturing vaccines
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
The vaccine was 85 percent effective in preventing severe disease across all regions.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
